PURE Bioscience, Inc. — Revenue by Fiscal Year
15 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d2a0e2ca-2b65-4658-bb51-8be7608e5161/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $2.2M | 2024-08-01 – 2025-07-31 | evidence 0001493152-25-020065 |
| FY 2024 | $2.0M | 2023-08-01 – 2024-07-31 | evidence 0001493152-24-042939 |
| FY 2023 | $1.9M | 2022-08-01 – 2023-07-31 | evidence 0001493152-23-038673 |
| FY 2022 | $1.9M | 2021-08-01 – 2022-07-31 | evidence 0001493152-22-029844 |
| FY 2021 | $3.9M | 2020-08-01 – 2021-07-31 | evidence 0001493152-21-026623 |
| FY 2020 | $6.9M | 2019-08-01 – 2020-07-31 | evidence 0001493152-20-019153 |
| FY 2019 | $1.9M | 2018-08-01 – 2019-07-31 | evidence 0001493152-19-016126 |
| FY 2018 | $1.8M | 2017-08-01 – 2018-07-31 | evidence 0001493152-18-014849 |
| FY 2017 | $1.8M | 2016-08-01 – 2017-07-31 | evidence 0001493152-18-014849 |
| FY 2016 | $1.3M | 2015-08-01 – 2016-07-31 | evidence 0001493152-16-014317 |
| FY 2015 | $729.0k | 2014-08-01 – 2015-07-31 | evidence 0001558370-15-001985 |
| FY 2014 | $550.0k | 2013-08-01 – 2014-07-31 | evidence 0001193125-14-385128 |
| FY 2013 | $820.0k | 2012-08-01 – 2013-07-31 | evidence 0001193125-13-409928 |
| FY 2012 | $812.0k | 2011-08-01 – 2012-07-31 | evidence 0001079973-12-000838 |
| FY 2011 | $454.0k | 2010-08-01 – 2011-07-31 | evidence 0001079973-12-000838 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
PURE Bioscience, Inc. — all facts · Net Income · Operating Income